EnsiliTech
Creating biologicals without refrigeration.
Creating biologicals without refrigeration.
EnsiliTech is a biopharmaceutical startup founded in 2022, based in the United Kingdom, with a vision to revolutionize vaccine storage and transportation. The company's groundbreaking ensilication technology forms protective silica nanoshells around vaccine components, allowing them to be stored and transported without refrigeration. This innovative approach not only extends the shelf-life of vaccines but also eliminates the need for the cold chain infrastructure, making them more accessible globally.
The recent £900.00K Pre Seed Round investment on 17 January 2023 attracted notable investors including Innovate UK, The Fink Family Office, Elbow Beach Capital, Science Angel Syndicate, QantX. The company is actively seeking partners to further develop technologies that are independent of cold chain requirements, with a focus on oral and mucosal delivery of vaccines and therapeutics for humans and animals.
EnsiliTech's mission to address the challenges associated with vaccine spoilage and inefficient cold chain distribution presents a compelling opportunity for investors and potential partners who are passionate about advancing global healthcare accessibility and sustainability.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Pre Seed Round | £900.00K | 5 |
|
17 Jan 2023 |
| Grant | £300.00K | 1 |
|
17 Jan 2023 |
No recent news or press coverage available for EnsiliTech.
We care about your data, and we'd love to use cookies make your experience better.
